With Exclusivity For Single-Dose Plan B, Teva Stays One Step Up On Generics
This article was originally published in The Tan Sheet
Executive Summary
Teva Pharmaceutical Industries likely will gain another three years of exclusivity in the branded nonprescription emergency contraceptive market with FDA's approval of a revised dosage of Plan B